NEW DRUG – Adasuve (loxapine inhaler) for rapid tranquillisation
Adasuve (loxapine inhaler) has been licensed in the EU for the rapid control of mild to moderate agitation in adult patients with schizophrenia or bipolar disorder.
The use of an inhaler for rapid tranquillisation to manage agitation is a novel method for administering medication. It has the advantage of not requiring an injection, but would require the patient to be compliant with treatment.
“This is a summary of the European Public Assessment Report (EPAR) for Adasuve. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Adasuve.”